CytoVeris
Farmington
About CytoVeris
CytoVeris develops optical-based technologies enabling surgical oncologists to identify and remove tumor tissue during cancer resection surgery. The Company's devices help to improve the surgeon’s ability to ensure clean margins are attained. It also develops technology to detect molecular signatures that cancer cells create due to the way that they hijack the cellular metabolic processes and corrupt DNA and protein pathways which creates signature variations of molecules such as lipids, proteins, and metabolites that can be detected with their OncoMap system. It was formed by Alan Kersey in Farmington, Connecticut in 2018.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $8.0M
- Funding stage: Early Stage Venture
- Last round: Non-Equity Assistance (May 2024)
- Website: cytoveris.com
- Phone: 860 657 6947
Industries & Categories
Health Care, Health Diagnostics, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/cytoveris-16920 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.